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Protein kinase Ds (PKDs) are diacylglycerol (DAG)-regulated serine/threonine protein kinases. 
In intact cells, PKDs are key mediators in cellular processes pertaining to multiple diseases, 
including cancer, heart diseases, angiogenesis and immune dysfunctions. A number of the novel, 
potent, and structurally diverse ATP-competitive PKD inhibitors have been reported to 
selectively modulate the PKD activity and thus, to achieve a potential therapeutic effect on 
related diseases. Due to a lack of the crystal structure, we have constructed a 3D structure of the 
human PKD1 protein by using homology modeling. Then, by using our established protein 
docking protocol, we docked novel PKD inhibitory small molecules and found the hit 
compounds exhibiting higher binding scores with reasonable binding mode in comparison with 
the reported active PKD1 inhibitors. Also, we calculated both 2D and 3D molecular similarity 
between our identified compounds and previously reported PKD1 inhibitors. Moreover, we 
predicted the possible off-targets of our compounds and our prediction has been validated 
through a topomer similarity study. In this study, we demonstrated that computational tools, i.e., 
docking and molecular similarity calculation can be applied to explore the PKD1/inhibitor 
interactions. In addition, the docking studies and the detailed docking poses provide insight for 
better understanding of the possible mechanism of a bioactive PKD1 inhibitor in order to guide 
future optimization for new drug design and discovery.  
 
PKD1 Structure and Docking Studies for New PKD Inhibitors 
Qi Xu, M.S. 
University of Pittsburgh, 2013
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1.0  INTRODUCTION 
1.1 PURPOSE OF STUDY 
The purpose of this study is to carry out a computational docking study of new PKD1 inhibitors 
on the 3D structural homology model of the kinase domain (residues 587 to 835) of human 
PKD1 in order to explore the interactions of PKD1 inhibitors in assisting future structure-based 
design. 
1.2 PROTEIN KINASE AND SMALL MOLECULE KINASE INHIBITOR 
1.2.1 Protein kinases 
Protein kinases are kinase enzymes that modify other proteins by chemically 
adding phosphate groups to them (phosphorylation) which usually results in a functional change 
of the target protein (substrate) and the subsequent alternation of cellular processes including 
proliferation or apoptosis1,2. Protein kinases can be classified based on substrate specificity or 
amino acid sequences of the catalytic domains. For the first one, kinases are classified by the 
amino acids they phosphorylate. The two main classes of kinases are tyrosine kinases (TKs), 
which phosphorylate tyrosine, and serine-threonine kinases, which phosphorylate serine or 
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threonine. Tyrosine kinases, the first identified and can, in turn, be classified into receptor or 
non-receptor tyrosine kinases. The former are transmembrane proteins with a ligand-binding 
extracellular domain and a catalytic intracellular kinase domain; the later lack a transmembrane 
domain and are located in the cytosol, the nucleus, and the inner surface of the plasma 
membrane3. The second classification relies on amino acid sequence comparisons of the catalytic 
domains. The human protein kinase family can thus be divided into seven main groups: the AGC 
family containing the protein kinases A, G and C; the CAMK family containing Ca2+/CAM-
dependent protein kinases; the CK1 family containing the casein kinase 1 group; the CMGC 
family containing CDK, MAPK, GSK3, and CLKs; the STE family containing homologues of 
yeast sterile 7, 11, 20 kinases; the TK family containing tyrosine kinases; and the TKL family 
containing tyrosine kinase-like PKs4. (Figure 1) 
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Figure 1. Overview of Human Protein Kinase Protein Family (www.cellsignal.com) 
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Protein kinases play key roles in intracellular signaling pathways which regulate cell 
growth, differentiation, development, functions, and death5. Mutations dysregulation of protein 
kinases, and aberrantly-regulated kinase activity are implicated in a wide range of human 
disorders, particularly several types of cancer, making protein kinases the second most important 
group of drug targets (after G-protein-coupled receptors2,6-9). In the early 1980s, Hiroyoshi 
Hidaka discovered that Naphthalene sulphonamides, such as N-(6-amino-hexyl)-5-chloro-1-
naphthalenesulphonamide (W7), which act as antagonists of the calcium-binding 
protein calmodulin were also able to inhibit a number of different protein kinases at higher 
concentration. By replacing the naphthalene ring with isoquinoline, Hidaka identified a group of 
ATP-competitive protein kinase inhibitors7. Scientists have since been making efforts to 
understand the biology of kinases and their role in disease as well as discovering new kinase 
inhibitors. In fact, more than twenty drugs target on protein kinases and the receptors that 
activate them have been launched or are in development.  Imatinib mesylate (marked by Novartis 
as Gleevec)10, for instance, is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl kinase 
through blocking ATP binding. Imatinib has been approved for the treatment of multiple cancers 
including Bcr-Abl-positive chronic myeloid leukaemia (CML) and Kit (CD117)-positive 
gastrointestinal stromal tumor.  
1.2.2 The binding sites of small molecule kinase inhibitors 
Most of the small molecule kinase inhibitors are ATP-competitive. The binding sites of these 
kinase inhibitors share certain characteristics: conserved arrangements into 12 subdomains that 
fold into a bi-lobed catalytic core structure with ATP binding in a deep cleft between the lobes; 
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conserved activation loop marked by conserved DFG and APE motifs at the start and end of the 
loop respectively; small molecules form one to three hydrogen bonds to amino acids located in 
the hinge region, thereby mimicking the hydrogen bonds that are normally formed by the 
adenine ring of ATP11. The majority of ATP-competitive inhibitors belong to the type I 
inhibitors which recognize the so-called active conformation of the kinase. (Figure 2a) These 
types of kinase inhibitors bind in and around the region occupied by the adenine ring of ATP 
(known as the adenine region) and do not require the DFG motif in the activation loop to adopt a 
‘DFG-out’ conformation for binding. Type I inhibitors mimic the exocyclic group of adenine and 
typically form approximately one to three hydrogen bonds with the kinase hinge residues that 
link the N- and C-terminal kinase domains12. In contrast, type II kinase inhibitors, such as 
Imatinib recognize the inactive conformation of the kinase. (Figure 2b) In this conformation, the 
DFG motif is rearranged and the movement of the activation loop exposes an additional 
hydrophobic biding site near the ATP binding site.  
 6 
 
 
Figure 2: Protein kinase inhibitor binding mode. a. Protein kinase ABL1 in complex with the type 1 ATP-
competitive inhibitor PD166326 (PDB ID 1OPK)11. b. The DFG-out conformation of the activation loop of 
ABL1 (dark blue) with the type 2 inhibitor imatinib (PDB ID 1IEP)13 
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1.3 PROTEIN KINASE D1 (PKD1) 
Protein kinase Ds (PKDs) constitutes a novel family of diacylglycerol (DAG)-regulated 
serine/threonine protein kinases that signal downstream of G protein-coupled receptors (GPCRs). 
Tyrosine kinase receptors belong to a distinct subgroup of the calcium/calmodulin-dependent 
protein kinase (CAMK) family. Previous studies show that PKDs are activated by DAG 
responsive PKCs through phosphorylation of S744 and S748 in the activation loop PH domain. 
This DAG/ PKC/PKD axis has been demonstrated to be a crucial signaling pathway for the 
regulation of a variety of essential biological events14. 
A previous study showed that all three of the PKD isoforms (PKD1, PKD2 and PKD3) 
play key roles in cellular processes pertaining to multiple diseases especially in tumor growth, 
metastasis, and angiogenesis14,15. PKDs have been shown to be linked to several major signaling 
pathways vital to cancer development, most notably the VEGF and MEK/ERK signaling 
pathway. This gives support to the tumor-associated role of PKD in diverse cancer types 
including breast cancer, pancreatic cancer, prostate cancer, basal cell, skin, gastric, lung and 
lymph15. Moreover, PKDs target the class IIa histone deacetylases (HDAC 4, 5, 7, 9) which in 
turn activate the hypertrophic response of the heart. Gain- and loss-of-function approaches were 
used in assessing the role of PKD1 in heart muscles which indicate an enhanced PKD1 catalytic 
activity in pathological cardiac hypertrophy animal models16. Mice lacking cardiac PKD1 exhibit 
a decreased response to stress signals that normally lead to cardiac hypertrophy, fibrosis, and 
fetal gene activation, indicating a critical role of PKD in this pathological process17. As such, 
PKD has emerged as a potential therapeutic target for cancer, cardiac hypertrophy, and other 
diseases18. 
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2.0  MATERIAL AND METHOD 
2.1 HOMOLOGY MODEL GENERATION 
Due to the lack of a PKD1 crystal structure, we generated the 3D homology models for PKD1 by 
using the I-TASSER server. The I-TASSER server is an internet service for protein structure and 
function predictions; I-TASSER was ranked as the number 1 server in the recent Critical 
Assessment of Techniques for Protein Structure Prediction (CASP9, 2010) competition for 
homology modeling and threading19,20. Academic users input amino acid sequences which the 
program translates into a 3D structure with high-quality predictions of biological function of 
protein molecules. Using this process, several template proteins of similar folds were retrieved 
by the server from the PDB library by LOMETS, a locally installed meta-threading approach. 
These templates go further into fragmentation and reassemble into full-length models, with the 
threading unaligned regions built by ab initio modeling and identified for lower energy states. A 
second simulation was done to cluster the decoys and select the lowest energy models. (Figure 3)  
The PKD1 kinase domain sequence, which started from Glu587 to Ser835 was submitted 
to the I-TASSER 3D structure prediction server, producing five similar models for PKD1 kinase 
domain. Protein structures 1ql6_A (rabbit, phosphorylase kinase), 2bdw_A (caenorhabditis 
elegans,  calcium/calmodulin activated kinase II), 3mfr_A (human, calcium/calmodulin (CaM)-
activated serine-threonine kinase), 2jam_B (human, calcium/calmodulin-dependent protein 
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kinase type 1G), and 2y7j_A (human, phosphorylase kinase, Gamma 2) were chosen by I-
TASSER as the templates in the modeling19.  
 
Figure 3. Protein 3D structure models generation by I-TASSER server. The protein chains are colored from 
blue at the N-terminus to red at the C-terminus19. 
2.2 PARAMETER SETTINGS OF DOCKING PROGRAM 
All the docking calculations were performed on Sybyl x1.3 by using the Surflex-Dock Method 
followed by our established protocols21,22. Surflex-Dock uses an empirical scoring function from 
the Hammerhead docking system and a patented search engine to dock ligands into a protein's 
binding site. It is particularly successful at eliminating false positive results and can, therefore, 
be used to narrow down the screening pool significantly, while still retaining a large number of 
active compounds.  
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2.2.1 The Surflex-Dock Protomol 
The Surflex-Dock Protomol is referred to as the “binding pocket”, a computational 
representation of the proposed binding site in which target small molecules are aligned. 
Generally, the protomol was constructed by the following processes. First, the selected protein 
surface is coated with certain types of probes representing potential hydrogen bonds and 
favorable hydrophobic interactions with protein atoms. The probes are positioned and oriented 
by a score function representing the binding contribution of a similar atom on a ligand. 
Furthermore, the probes are filtered by score resulting in a cluster of high-scoring probes which 
identify the “sticky parts” of the protein’s surface. Disconnected sticky spots are discarded with 
the rest form spheres on a 1 Å cubical grid. Each spheres grows until it reaches the van der 
Waals surface of a protein atom; sphere with a radius less than 0.5 Å are discarded. Finally, the 
sticky spots are merged into a pocket by accretion on the set of remaining protein-free spheres23.  
In our study, the protein kinase domain models were first modified by adding all 
hydrogens. The docking area was defined by a pocket set to cover the ATP binding domain of 
the protein. Protomol construction was based both on protein residues Ala610, Lys612, Met659, 
Glu660, Lys661, Leu662, His663, Glu710, Leu713, Cys726, and on parameters set to produce a 
small and buried docking target24. (Figure 4) Similar to the type 1 inhibitor, the 
alkylaminopyridine shown in the figure forms two hydrogen bonds with the Leu662 hinge 
residue; the naphthyridine 6-nitrogen contacts with the catalytic Lys612, and the piperazine 
nitrogen participates a salt bridge with a pendent Glu710 of the sugar pocket. Two parameters 
(protomol_bloat and protomol_threshold) determine the extent of the protomol and the docking 
performance depends on the binding site (protomol). We chose the parameter: 
protomol_threshold of 0.6 and protomol_bloat of 3.0. This was sufficient for generating a small 
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and adequate pocket for docking. (Figure 5) We treated all five models with the same protomol 
and docking was run with default settings for all other parameters. 
2.2.2 The Surflex-Dock Docking Procedure 
Surflex-Dock GeomX (SFXC) was chosen to be the docking mode in which twenty additional 
starting conformation per molecule were added25. In our study, we allowed for flexibility of 
protein atoms whose van der Waals distance from ligand atoms were less than 4 Å and adapted 
the active site conformation to the docked ligand. (Figure 6) PKD1 small molecule inhibitors 
were translated into SDF files and minimized to keep the lowest energy state. We entered both 
the protomol and the prepared 3D small molecule ligand into the Surflex-Dock program and 
started the calculation. The Surflex-Dock scoring function is a weighted sum of non-linear 
functions involving van der Waals surface distances between the appropriate pairs of exposed 
protein and ligand atoms. The list of atom pairs of interest is established by pruning out all 
protein-ligand atom pairs for which the distance between their van der Waals surfaces is greater 
than 2 Å. Each atom in the remaining protein-ligand pairs is labeled as being non-polar (e.g. H in 
CH3) or polar (e.g. H in N-H or O in C=O)26.  
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Figure 4: Proposed key contacts for PKD inhibitor 13c in PKD124.  
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Figure 5. Surflex-Dock Protomol for PKD1 3D homology model 3.  
2.3 STRUCTURAL COMPARISON BETWEEN OUR COMPOUNDS AND KNOWN 
PDK1 INHIBITORS 
In order to evaluate the molecular similarity between our active compounds and known PKD1 
inhibitors, both 2D and 3D similarity methodologies were employed to compare these 8 
compounds against 18 previously reported PKD1 inhibitors as well as ATP27.  
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2.3.1 2D molecular similarity study 
UNITY 2D search was used to calculate the Tanimoto scores based on the computation and 
comparison between the fragment bitmaps of two structures. These fragment bitmaps are often 
referred to as "fingerprints," and have bits set according to the fragments found in the structure. 
The Tanimoto coefficient scores (SimT) can be calculated as:  
 SimT=C/ (A+B-C) 
where C is the count of bits set in both fingerprints, A is the count of bits set in fingerprint #1, 
and B is the count of bits set in fingerprint #2. The TS (Tanimoto score) range from 0.0 to 1.0, 
where a large TS score implies two chemicals similar in their 2D structures28-31.  
2.3.2 3D molecular similarity study 
The Surflex-Sim 3D similarity program was used to calculate the morphological similarity score 
(MSS). Scores ranged from 0.0 to 10.0, with large values indicating two compounds with similar 
3D shapes32. Surflex-Sim is a 3D molecular similarity optimization and searching program 
which applies a morphological similarity function and fast pose generation techniques to 
generate alignments of molecules. Surflex-Sim bases similarity on a molecule's shape, hydrogen 
bonding and electrostatic properties. The program considers molecular surfaces, not volumes, 
thus molecules of different sizes are handled easily by Surflex-Sim. 
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3.0  RESULTS 
3.1 STRUCTURE MODELING OF PKD1 KINASE DOMAIN 
Five models defined as models 1 through 5 were chosen based on the best C scores which were 
calculated to show that their 3D structures present similar topologies and overall shapes. (Figure 
5)19 Although the sequence identities between PKD1 and their templates are moderate 
(approximately 30% to 37%), their 3D structures present similar topologies and overall shapes. 
Specifically, conserved structure elements fold into a bi-lobed catalytic core structure with ATP 
binding in a deep cleft located between the lobes. These observations support our strategy to take 
advantage of the structural conservation in the PKD1 kinase domain to identify the key residues 
for inhibitor-protein interactions and then search for equivalent residues. 
 
Figure 6. Top five models generated by I-TASSER. C-score was calculated to show that their 3D structures 
present similar topologies and overall shapes18. 
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A total of 28 bioactive PKD1 inhibitors selected from 235 compounds were docked into the PKD 
kinase domain binding sites for all five models. Surflex-Dock scores are expressed in -log10(Kd) 
units to represent binding affinities. Here we show the resulting model 3 and 4, which have the 
highest docking scores. (Table 2) The docking scores of the bioactive molecules together with 
their inhibition are shown in Table 1. All docking scores ranged from 4 to 9, which can be 
correlated to Kd values of 100 mM to 1 nM, respectively33. For docking programs and scoring 
functions, a number of false positives would usually appear in the top ranking list. It is necessary 
to manually check and analyze the binding mode of each compound to determine if it has 
reasonable interaction and geometry fitting. Those molecules with binding modes exhibiting 
large differences with the corresponding existing compounds were excluded from the list after 
this inspection. Taking the binding score, inhibition, and binding mode into consideration, a 
representative hit, RO3202312-001 (renamed as compound 139) was found to dock well with the 
PKD kinase domain binding site in models 3 and 4. The structure of this validated hit was 
identified and its interaction with PKD kinase domain binding site is shown in Figure 6. Note 
that, the NH2 and OH group form hydrogen-bonding interactions with the back bone of Leu662 
and Gly664, located in the hinge region. The fluorine atom on the benzene ring and the nitrogen 
atom of the pyridine were observed to interact with the charged NH3+ of Lys612. These 
interactions are in conformity with the reported binding mode of experimentally tested previous 
PKD1 inhibitors24. The hydrogen-bonding interactions between the hydroxyl group of the hit and 
Leu662 as well as Glu660 are acknowledged as common to all of the previously known PKD1 
inhibitors. However, we did not observe another common hydrogen-bonding interaction between 
our hit molecule and Clu710. Instead, an unoccupied pocket next to the indole nitrogen atom 
suggests the substitution at this position may be well tolerated. 
 17 
 
Figure 7. Molecular modeling of compound 139 in the active site of a PKD1 homology model. A. The docking 
result of the bioactive compound 139 in the ATP binding site of the PKD1 kinase domain. Carton ribbon and 
thick line, PKD1; ball and stick, Compound 139; thin line, residues in the binding pocket; magenta line, 
hydrogen bond. B. The proposed key contacts in the active site. Purple line, hydrogen bond; residues in 
different colors: purple, basic; pink, acidic; green, hydrophobic; gray, hydrophilic18. 
 
 
Compound ID Inhibition 
Model3 Model4 
Total 
score 
Crash Polar 
Total 
score 
Crash Polar 
ro0272159-000 55% 4.8858 -0.6717 0.5727 5.9596 -0.9128 3.0941 
ro0281601-001 94% 6.9009 -1.3660 1.9981 7.2726 -1.2405 3.8065 
ro0282155-000 80% 8.1487 -1.2844 2.1006 7.2622 -1.9783 2.7245 
ro0282986-001 97% 7.8100 -1.3037 1.7776 6.7615 -0.8366 1.4902 
ro0283049-001 95% 7.8903 -1.9141 5.5857 7.6094 -0.8638 3.0703 
ro0283120-000 97% 7.5244 -2.7031 3.3006 8.0268 -3.4905 4.9235 
ro0317253-000 54% 5.5374 -0.2949 1.2629 5.5452 -1.9602 2.2220 
ro0317340-000 65% 6.5484 -1.4297 0.5104 5.7383 -3.7040 2.1839 
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ro0317377-000 65% 6.8866 -1.5538 2.7313 7.6009 -0.9385 1.7922 
ro0480500-002 77% 8.3315 -3.9738 2.0981 8.1414 -3.5176 4.7950 
ro0504833-000 86% 6.3595 -0.6336 3.4251 6.7998 -0.6228 3.2615 
ro0504985-000 93% 7.6159 -1.7532 5.4655 6.7209 -0.6299 5.9762 
ro0506220-000 65% 6.5284 -2.7029 2.4351 7.8633 -1.0306 2.4698 
ro1153853-000 86% 5.2845 -0.9685 1.9311 4.9812 -0.9037 1.0894 
ro1155240-000 55% 5.3839 -0.4834 0.2696 4.7941 -0.2906 0.0153 
ro1155697-000 62% 5.0076 -0.8801 0.8249 5.3993 -1.2469 2.3886 
ro1155798-000 58% 7.3376 -0.8577 2.2108 6.5969 -2.7463 3.1254 
ro3202312-001 94% 9.0223 -0.8286 2.2653 8.3194 -1.4282 3.7485 
ro3206145-001 80% 7.7077 -1.7656 4.1853 8.4016 -1.6166 2.0628 
ro4241967-000 62% 3.5125 -0.3827 0.9004 6.0081 -0.9309 2.7081 
ro4367842-001 78% 7.5907 -1.1975 2.3250 6.7506 -1.3341 2.2950 
ro4442080-000 55% 5.9590 -1.3500 1.0243 6.2918 1.0300 1.5459 
ro4503319-000 49% 6.8369 -1.3919 0.0914 7.1934 -1.5664 3.7593 
ro4509200-000 62% 7.2031 -1.6132 0.2601 7.5887 -1.1101 2.4558 
ro4554339-000 85% 6.1197 -1.3313 0.1721 5.7010 -1.9621 1.7506 
ro4569139-000 82% 5.4102 -1.0296 2.5235 4.8094 -0.9669 1.9553 
ro4595949-000 64% 4.9175 -0.7034 1.7907 4.7002 -1.1703 2.2313 
Table 1. Docking result of the novel PKD1 inhibitors in model 3 and model 4. Total score indicates the 
binding score between the small molecule ligand and the PKD model. Compound ro3202312-001 is the same 
as hit compound 139 (renamed afterwards).  
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3.2 STRUCTURAL DIVERSITY ANALYSIS 
A structural diversity analysis was done between eight PKD1 selective compounds and 18 
known PKD1 inhibitors as well as ATP. Here, we show the results for the three most promising 
compounds: 122, 139, and 140. The 3D MSS ranged from 3.29 to 7.10 and the 2D Tanimoto 
scores ranged from 0.174 to 0.544. (Table 2) Indicating that the three novel compounds 
increased the structural diversity of PKD1 inhibitors. 
 
Compound ID 
122 139 140 
UPCMLDRO1155697-000 UPCMLDRO3202312-001 UPCMLDRO3206145-001 
 
MSS TS MSS TS MSS TS 
CID_2876479 5.41 0.196 6.53 0.245 6.79 0.238 
CID_755673 5.57 0.201 6.96 0.223 7.08 0.228 
CID_646236 5.58 0.287 6.14 0.297 6.35 0.302 
CID_5086667 5.92 0.231 6.78 0.276 6.58 0.277 
CID_2958734 5.90 0.267 4.94 0.340 5.17 0.349 
CID_16230 4.97 0.199 6.45 0.239 6.34 0.236 
CID_4438738 4.98 0.232 7.04 0.219 7.05 0.217 
CID_663844 4.98 0.319 4.98 0.359 5.32 0.371 
CID_5389142 4.60 0.354 6.80 0.434 7.10 0.456 
CID_9549170 4.70 0.304 5.39 0.341 5.63 0.349 
CID_2011756 3.46 0.219 4.23 0.289 4.38 0.291 
CID_1893668 3.29 0.174 4.39 0.234 4.61 0.235 
ATP 5.85 0.265 5.47 0.290 5.76 0.305 
kb-NB142-70 4.83 0.177 5.46 0.207 5.46 0.212 
BPKDi 5.77 0.362 5.67 0.513 5.49 0.523 
 20 
13c 5.61 0.379 5.97 0.544 5.51 0.530 
24c 4.91 0.273 5.94 0.334 5.91 0.340 
CRT5 5.63 0.316 5.32 0.404 5.73 0.410 
12a 4.90 0.362 5.19 0.513 4.91 0.523 
Table 2: Structural diversity analysis results. 2D and 3D similarity search between the three most promising 
new PKD1 inhibitors and 18 known PKD1 inhibitors as well as ATP. 
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4.0  DISCUSSION 
In this study, a 3D PKD1 protein structure was generated through homology modeling and 
verified by newly synthesized small molecule PKD1 inhibitors in the subsequent docking studies. 
All ligands were docked into the assumed ATP binding pocket of the kinase domain, resulting in 
relatively high docking scores. Among them, our lead compound 139 formed a reasonable 
binding mode not different with the previous reports. Furthermore, structural diversity analysis 
demonstrated an increase in diversity of three representative compounds. 
We also performed the Topomer similarity study between new PKD1 inhibitors and the 
PDB ligand library. Possible off-target effects of new PKD1 inhibitors were identified as a result. 
The identified compounds were similar to an inhibitor of CDK2 (FMD), which was co-
crystallized with CDK2 in PDB 1R7834. Compound 16 was docked into the kinase domain of 
CDK2 with a docking score of 10.92 and a nearly overlapped binding mode with FMD. (Figure 7) 
Additionally, our lead compound 139 was found to be similar to the p38 kinase inhibitor (FPH) 
which was co-crystallized with P38 kinase in PDB 1OZ135. Docking studies give a docking score 
as high as 13.3 for compound 139 with p38 kinase. These possible off-target effects give further 
direction to the study of new PKD1 inhibitors to discover their role in other protein kinases and 
the PKD signaling transduction pathway. Taken together, the computational tools proved to be 
useful in many aspects of small molecule discovery processes including exploring the possible 
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mechanism of a bioactive compound, guiding future optimization, or finding possible off-targets 
of small molecules. 
     
Figure 8. Possible off-target effect of PKD1 inhibitors. In the left figure compound 16 was docked into CDK2 
PDBID: 1R78 (CDK2 co-crystallized with FMD). Ball and sticks represent compound16; lines represent FMD. 
In the right figure, compound 139 was docked into P38 PDB: 1OZ1 (P38 co-crystallized with FPH, FPH is not 
shown here) 
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5.0  FUTURE SPECULATION 
One of the biggest obstacles in developing protein kinase inhibitors is their PKD1 selectivity in 
that the ATP binding site of protein kinases share similar arrangements and shapes. The possible 
off-target effects of new PKD1 inhibitors indicates that these small molecules may require 
structural optimization in order to increase their selectivity. In comparison with the proposed key 
contact or binding residues of PKD1 in the reported study, we found that our screened hit 
compounds lack the important interaction with Glu 710, while retaining an unoccupied pocket 
between the pyrrole ring and Glu 710. Hence, we hypothesize that introducing a piperazine ring 
on the pyrrole ring may increase the binding affinity and enhance the selectivity of the PKD1 
inhibitors. This could be an interesting direction for future search. 
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Figure 9. Comparison between compound 139 and the reported PKD1 inhibitor 13c. Proposed structural 
modification was shown in the blue rectangle. 
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APPENDIX A 
PROTOCOL 
A.1 HOMOLOGY MODELING 
1. Open I-TASSER online server. 
2. Write the PKD1 sequence in FASTA format. Load the sequence onto the server. 
3. The models will be sent by e-mail the following day. 
A.2 DOCKING STUDY BY SURFLEX-DOCK. 
A.2.1 Initiating Surflex-Dock 
1. Open Sybyl X 1.3. 
2. File -> Import File: select the correct file type and choose the PKD1 model3. 
3. Edit -> Hydrogens -> Add All Hydrogens 
4. View -> Surface and Ribbons -> Quick Ribbons -> Ribbon. This step is not necessary for 
Docking study, but will give a better vision on both the protein and the kinase domain. 
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5. Application -> Docking Suites -> Dock ligands 
6. Docking parameters setting: Choose the Docking Mode as Surflex-Dock GeomX (SFXC). 
Different docking mode gives different criteria. In “Options”, click Surflex-Dock. Allow 
both Hydrogen and Heavy Atoms movement. Change the “Additional Starting 
Conformations per Molecule” into 20. Click “OK” to save the modification. 
7. On the right side of “Filename”, click “Define”.  
8. Binding pocket generation: Select the “Protein Structure” as “Mol Area” and then choose 
“M1: model3”. Define the “Mode” as “Residues”, and then choose the residues as shown in 
section 2.2.1. Set the “Threshold” as 0.6 and “Bloat” as 3. Click “Generate” to generate a 
new model. Change the file name and click “OK” to return to the Surflex-Dock main menu.  
9. In “Ligand Source”, select the corresponding file type and choose the file which contains 28 
bioactive PKD1 inhibitors. 
10. Change the Jobname and click OK to start the Docking process which takes approximately 
one day’s time. 
A.2.2 Analyzing Docking Result 
1. Application -> Docking Suite -> Analyze Results 
2. Click Jobname to start the analysis, all the 28 molecules with their total binding score were 
shown. 
3. Left click on molecule “RO3202312-001”, the interaction between the molecule and the 
protein was shown.  
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4. Close the result analyzing panel. Left click to select the residues which form hydrogen bond 
with the molecule. Then, right click and select atom display -> label -> substructure. The 
residues will be labeled.  
A.3 STRUCTURAL DIVERSITY ANALYSIS 
A.3.1 UNITY 2D search 
1. File -> Import File. Open the file contains 18 know PKD1 inhibitors and ATP. 
2. Select and click File -> Put Rows into UNITY database. Close the dialog. 
3. UNITY -> UNITY tools -> translate molecular files. Translate the 8 new PKD1 inhibitors 
into SLN file. 
4. UNITY -> Start UNITY Search. Select “Other Database” in the “Open Database” section. 
Click “Open” to load the new database. Open one of the translated SLN files, copy the 
content and paste under “Search Query in SLN”. Select “2D Similarity” in the “Query Type”. 
Make a Job name and click OK to run the search. 
5. UNITY -> Search Management: the searching status is shown in the panel. Click “Load into 
table” to see the results. 
6. Perform same process to complete UNITY 2D similarity search for all 8 new inhibitors. 
A.3.2 Surflex-Sim 3D similarity search 
1. Applications -> Similarity Suite -> Surflex-Sim. 
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2. Select “Surflex-Sim Flexible Superposition” as Similarity Mode.  
3. Translate 8 new inhibitors into Mol2 Files. Use one as Template.  
4. Put all 18 known inhibitors and ATP in a SDF file. Load this file on “Ligand Source” and 
select “SD file”. 
5. Make a Jobname and click OK to run the search. 
6. Applications -> Similarity Suite -> Analyze Results. Find the search in Jobname and see the 
results in the table. Select the new inhibitor in “View” and the known inhibitors or ATP in 
the table to compare their 3D similarity. 
7. Perform the same research for all 8 new inhibitors. 
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